These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 30623554)

  • 1. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group.
    Gild P; Vetterlein MW; Seiler R; Necchi A; Hendricksen K; Mertens LS; Roghmann F; Landenberg NV; Gontero P; Cumberbatch M; Dobruch J; Seisen T; Grande P; D'Andrea D; Anract J; Comploj E; Pycha A; Saba K; Poyet C; van Rhijn BW; Noon AP; Roupret M; Shariat SF; Fisch M; Xylinas E; Rink M
    Surg Oncol; 2020 Sep; 34():312-317. PubMed ID: 32891350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
    Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP
    BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Tarrel R; Quevedo FJ; Cheville JC; Karnes RJ
    World J Urol; 2019 Nov; 37(11):2409-2418. PubMed ID: 30805684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
    Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
    BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    Eur Urol Oncol; 2019 Jul; 2(4):390-396. PubMed ID: 31277775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
    Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
    Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A
    Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
    Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
    J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
    Kim PH; Kent M; Zhao P; Sfakianos JP; Bajorin DF; Bochner BH; Dalbagni G
    World J Urol; 2014 Apr; 32(2):453-9. PubMed ID: 23842986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Prognostic Value of Tumor Regression Grades Combined With TNM Classification in Patients With Muscle-Invasive Bladder Cancer Who Underwent Neoadjuvant Chemotherapy Followed by Radical Cystectomy.
    Gronostaj K; Czech AK; Fronczek J; Drobniak A; Okon K; Chlosta PL; Szczeklik W
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1203-e1211. PubMed ID: 31588010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].
    Pignot G; Houédé N; Roumiguié M; Audenet F; Brunelle S; Colin P; Compérat E; Larré S; Masson-Lecomte A; Neuzillet Y; Xylinas E; Méjean A; Rouprêt M;
    Prog Urol; 2018 Oct; 28(12):567-574. PubMed ID: 30205925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].
    Michel C; Vordos D; Dumont C; Basset V; Meyer F; Gaudez F; Meria P; Cortesse A; Mongiat-Artus P; de la Taille A; Culine S; Desgrandchamps F; Masson-Lecomte A
    Prog Urol; 2018 Sep; 28(10):495-501. PubMed ID: 29997033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
    Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
    J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
    Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
    Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy.
    Parker WP; Ho PL; Boorjian SA; Melquist JJ; Thapa P; Holzbeierlein JM; Frank I; Kamat AM; Lee EK
    World J Urol; 2016 Nov; 34(11):1561-1566. PubMed ID: 26943643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Gender on Chemotherapeutic Response and Oncologic Outcomes in Patients Treated With Radical Cystectomy and Perioperative Chemotherapy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Kimura S; Iwata T; Abufaraj M; Janisch F; D'Andrea D; Moschini M; Al-Rawashdeh B; Fajkovic H; Seebacher V; Egawa S; Shariat SF
    Clin Genitourin Cancer; 2020 Apr; 18(2):78-87. PubMed ID: 31889669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.